After grabbing 7.45 million shares, the institutional investor is now in possession of 7.45 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.17% having worth around $1.69 million. Moreover, Apo Asset Management GmbH increased its share by 0.39 million to have a control over 0.88 million shares. And Acadian Asset Management LLC raised its holdings to 0.66 million shares by acquiring 0.66 million shares or 0.72% of the stake.
RedHill Biopharma Ltd. (RDHL) concluded trading on 03/15/23 at a closing price of $0.18, with 2.21 million shares of worth about $0.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -78.57% during that period and on Wednesday the price saw a loss of about -0.56%. Currently the company’s common shares owned by public are about 63.84M shares, out of which, 34.99M shares are available for trading.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
FCP Medical – BioHealth, APO Medical Opportunities, and RIM Global – Bioscience are the top 3 mutual funds which are holding stakes in RedHill Biopharma Ltd. FCP Medical – BioHealth is currently holding 1.17 million shares of worth totaling $0.27 million. The company recently came buying 0.0 shares which brought its stake up to 1.28% of the company’s outstanding shares. APO Medical Opportunities bought 0.34 million shares, after which its hold over company’s outstanding shares expand to 0.79%, leaving 0.72 million shares with the mutual fund that have a worth of about $0.16 million. RIM Global – Bioscience, after buying 0.21 million shares, have now control over 0.23% of the stake in the company. It holds 0.0 shares of worth $48115.0.
However, the stock later moved at a day high price of 0.1800, or with a loss of -0.56%. Stock saw a price change of -14.76% in past 5 days and over the past one month there was a price change of -14.76%. Year-to-date (YTD), RDHL shares are showing a performance of 27.58% which decreased to -89.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $3.27 during that period. The average intraday trading volume for RedHill Biopharma Ltd. shares is 6.42 million. The stock is currently trading -16.87% below its 20-day simple moving average (SMA20), while that difference is down -11.53% for SMA50 and it goes to -68.69% lower than SMA200.
Sabby Management LLC acquired 7.45 million shares of RedHill Biopharma Ltd. having value of about $1.69 million. RedHill Biopharma Ltd. (NASDAQ: RDHL) currently have 63.84M outstanding shares and institutions hold larger chunk of about 7.30% of that. Holding of mutual funds in the company is about 11.50% while other institutional holders and individual stake holders have control over 2.63% and — of the stake respectively.
The stock has a current market capitalization of $17.09M and its 3Y-monthly beta is at 2.26. It has posted earnings per share of -$1.62 in the same period. It has Quick Ratio of 0.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RDHL, volatility over the week remained 10.15% while standing at 8.30% over the month.
Analysts are in expectations that RedHill Biopharma Ltd. (RDHL) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -0.50%.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on August 31, 2021 offering an Overweight rating for the stock and assigned a target price of $22 to it. Coverage by H.C. Wainwright stated RedHill Biopharma Ltd. (RDHL) stock as a Buy in their note to investors on May 18, 2021, suggesting a price target of $23 for the stock. Stock get a Buy rating from WBB Securities on March 12, 2019.
Leave a Reply